HIV prevention has changed considerably with the development of long-acting medicines. While daily oral PrEP has been an important HIV prevention tool for many years, researchers are also developing longer-lasting approaches that could reduce the need for frequent dosing. One of these approaches is the HIV prevention implant. An implant is a small device placed under the skin that can gradually release an antiretroviral medicine over an extended period. However, an important distinction is necessary: HIV prevention implants are still investigational and are not currently FDA-approved for routine HIV prevention in the United States.
An HIV protection implant is an investigational long-acting HIV prevention technology.
The basic concept is relatively straightforward. A small implant containing an antiretroviral drug is placed under the skin, where it can gradually release medication into the body.
Instead of taking a PrEP pill every day or receiving an injection every few months, a future implant could potentially provide protection for a substantially longer period.
Researchers are investigating implants that could potentially provide HIV protection for periods ranging from several months to a year or longer.
An implant would be designed to maintain a therapeutic level of an antiretroviral medicine in the body.
The general process could involve:
The goal is to maintain enough medication in the body to prevent HIV from establishing an infection after exposure.
Not as a routinely approved HIV prevention method in the United States.
HIV.gov reports that researchers are studying long-acting prevention technologies including implants, but most HIV prevention implants remain in early development.
As of 2026, the FDA-approved long-acting PrEP products in the United States are injectable medicines:
These are injections, not implants.
Daily medication can be highly effective, but maintaining a daily dosing routine can be difficult for some people.
Researchers are investigating implants because they could potentially address several challenges associated with daily PrEP.
Potential advantages include:
NIH describes long-acting prevention research as an effort to create prevention methods that can be inserted, injected, infused, or implanted and provide sustained protection.
Daily oral PrEP requires medication to be taken consistently.
For people who take oral PrEP exactly as prescribed, it can reduce the risk of sexual HIV transmission by about 99%.
An implant would work differently by continuously releasing medication rather than requiring a daily dose.
| Feature | Daily Oral PrEP | Investigational Implant |
|---|---|---|
| Administration | Tablet | Small device under skin |
| Dosing | Daily | Potentially months or longer |
| FDA-approved for HIV prevention | Yes, depending on product | No |
| Routine availability | Yes | Clinical research |
| Medical visits | Periodic testing | Placement and follow-up |
| Daily pill burden | Yes | Potentially reduced |
The implant concept remains under investigation, so its eventual dosing duration, effectiveness, safety, and approval status will depend on clinical-trial results.
HIV prevention implants should not be confused with long-acting injectable PrEP.
Injectable PrEP is already available in the United States.
Apretude uses cabotegravir and is administered by a healthcare professional every two months. Yeztugo uses lenacapavir and is administered twice yearly.
Implants represent a different delivery method because the medication is released from a device placed inside the body.
If successful, implants could offer several potential benefits.
The most obvious potential benefit is reducing how often medication needs to be taken.
Instead of remembering a pill every day, a person could potentially receive an implant that releases medication for an extended period.
An implant could potentially fit into routines where daily medication is difficult to maintain.
Because the implant is positioned under the skin, researchers are investigating whether this type of prevention could provide a discreet alternative for people who prefer not to take visible medication.
A properly designed implant could continuously release medication at a controlled rate.
This could help maintain drug exposure without depending on daily pill-taking.
HIV testing is essential before starting PrEP.
PrEP is intended for people who do not have HIV. It is not HIV treatment.
Someone who has HIV requires an effective antiretroviral treatment regimen rather than PrEP alone.
Current PrEP guidance recommends regular HIV testing during prevention treatment, commonly every three months for people using PrEP.
An investigational implant would also require appropriate HIV testing and clinical monitoring.
If a person tests positive for HIV, PrEP is not the appropriate treatment.
HIV treatment uses combinations of antiretroviral medicines designed to suppress HIV replication.
Using inadequate HIV medication after infection could potentially contribute to drug resistance.
For this reason, HIV status must be confirmed before and during preventive treatment.
Drug resistance is an important consideration for all long-acting HIV prevention technologies.
If someone acquires HIV while medication concentrations are too low to fully prevent viral replication, resistant HIV could potentially emerge.
NIH notes that HIV acquisition while taking PrEP can, in rare cases, be associated with drug resistance.
This makes regular HIV testing and appropriate follow-up particularly important with long-acting prevention.
People seeking HIV prevention do not need to wait for an implant to become available.
Current prevention approaches include:
FDA-approved oral PrEP medications include Truvada and Descovy or appropriate generic equivalents.
Apretude is administered every two months, while Yeztugo is administered twice yearly.
Correct condom use can reduce the risk of HIV and several other sexually transmitted infections.
Post-exposure prophylaxis is a short course of HIV medicines used after a potential exposure.
PEP should be started as soon as possible and within 72 hours of exposure.
Implants are only one part of a larger effort to create long-lasting HIV prevention.
Researchers are investigating:
HIV.gov identifies implants, intravaginal rings, injectables, and antibodies as areas of long-acting HIV prevention research.
If an implant eventually receives regulatory approval, it could potentially be useful for people who:
Eligibility would depend on the specific product, clinical-trial evidence, regulatory approval, medical history, and prescribing requirements.
Because most HIV prevention implants are still investigational, their long-term safety profiles are not yet established.
Researchers must evaluate issues such as:
Investigational HIV medicines and technologies are studied in clinical trials to determine their safety, effectiveness, appropriate dosing, and potential risks before regulatory approval.
The intended duration depends on the technology being developed.
Researchers are investigating implants designed to provide sustained HIV prevention for periods ranging from months to potentially a year or longer.
However, a specific duration should not be assumed for investigational products.
The final dosing interval would depend on clinical evidence and regulatory approval.
HIV prevention during pregnancy and breastfeeding requires specialized medical consideration.
NIH recommends discussing PrEP with sexually active people without HIV who are trying to conceive, pregnant, postpartum, or breastfeeding when HIV prevention is relevant.
Because implant technologies are still investigational, pregnancy-related use would depend on the specific product and available safety data.
No HIV prevention medicine should be assumed to protect against other sexually transmitted infections.
PrEP reduces the risk of HIV but does not prevent infections such as:
Condoms and routine STI screening can provide additional protection.
Long-acting prevention does not eliminate medical follow-up.
A healthcare professional may need to monitor:
Regular monitoring helps ensure that prevention remains safe and effective.
Long-acting medicines can create a special consideration known as a drug tail.
After a long-acting product is removed or its medication release ends, drug levels may gradually decline rather than stopping immediately.
If medication levels become too low, HIV could potentially acquire resistance if infection occurs.
For this reason, discontinuation of a future implant would need to include an appropriate prevention plan determined by a healthcare professional.
It is also important to distinguish prevention implants from long-acting HIV treatment.
Prevention implants are intended for people who do not have HIV.
HIV treatment is intended for people living with HIV.
The medicines, goals, eligibility requirements, and clinical monitoring can differ.
Some long-acting HIV treatment approaches are already approved, but these are generally injectable rather than implantable.
HIV prevention implants represent an area of continuing research.
The broader objective is to create prevention methods that require fewer dosing events while maintaining strong protection against HIV.
A successful implant could potentially offer a combination of:
However, researchers still need to establish effectiveness, safety, appropriate drug concentrations, manufacturing standards, implantation procedures, and long-term outcomes.